• doctors working on iPad
  • patient smiling
  • man doing research with viles

TOLMAR – A Fully Integrated Pharmaceutical Company

TOLMAR is a fully integrated pharmaceutical company focused on the development, approval, and commercialization of specialty pharmaceutical products, including a line of generic dermatology products where TOLMAR is an established leader, and specialty injectable oncology products. Invention, development, and world-wide approval of ELIGARD for the palliative treatment of advanced prostate cancer has established TOLMAR as a leader dedicated to the urology community, providers, and patients. “TOLMAR” refers to TOLMAR Holding, Inc. and its wholly owned operating subsidiaries, TOLMAR Inc. (product development and manufacturing), TOLMAR Therapeutics, Inc. (licensing) and TOLMAR Pharmaceuticals, Inc. (sales and marketing). TOLMAR Pharmaceuticals is based in Lincolnshire, Illinois with TOLMAR’s headquarters, product development and manufacturing facilities based in Fort Collins, Colorado.

Dedication

TOLMAR is dedicated to working in partnership with the urology community, its providers, and most importantly, its patients. Passion fueled the invention, development, and advancement of ELIGARD, and it is passion that guides our commitment to providing the highest level of support to the urology community and patients with prostate cancer. Our highly experienced, commercial leadership team and specialty sales force embody dedication with purpose. TOLMAR is a leader in the dermatology product space dedicated to developing and manufacturing the highest quality products for our commercial partners.

Innovation

At TOLMAR, it is our mission to develop innovative pharmaceutical solutions to serve patients in need. TOLMAR research scientists, chemists, and engineers have developed an extensive portfolio of pharmaceutical products, including a broad line of dermatology products, and ELIGARD for the palliative treatment of advanced prostate cancer. TOLMAR is dedicated to advancing our pipeline of products and expanding our portfolio to serve important patient needs.